Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
550 Leser
Artikel bewerten:
(2)

Gentex Applauded by Frost & Sullivan for Its Comprehensive Powered Air Purifying Respiratory Solution Suite, PureFlo 3000

Finanznachrichten News

With its unique all-in-one approach, low total cost of ownership, and superior customer experience, the PureFlo 3000 series exceeds customer expectations

SANTA CLARA, Calif., March 10, 2021 /PRNewswire/ -- Based on its recent analysis of the North American powered air purifying respiratory (PAPR) protection equipment market, Frost & Sullivan recognizes Gentex Corporation with the 2020 North American New Product Innovation Award. Gentex's innovative PureFlo 3000 PAPR series enhances workplace safety by integrating protection with an unrivaled level of comfort. Features are configured to the needs of diverse industries, such as construction, food processing, light manufacturing, pharmaceutical manufacturing, welding, and healthcare. In addition, the series is optimized for settings such as smelters and nuclear power plants.

"The PureFlo 3000 offers true value through high efficiency, durability, compatibility and improved safety" said Rahul Arora, Best Practices Research Analyst at Frost & Sullivan. "Optimized for maximum mobility, the series combines respiratory with head, face, eye, and optional hearing protection for use in light-to-medium duty environments. In addition, the series eliminates snag hazards because it has no belts, hoses, or cables, and its loose-fitting design ensures it can be safely used by individuals with beards or prescription eyeglasses without requiring extensive fit testing."

Significantly, Gentex manufactures its protective hoods from a range of disposable materials to suit different industries and applications. In addition to application versatility and user comfort, the series enables a lower total cost of ownership. For example, the PureFlo 3000 offers a pre-filter and spark arrestor to reduce hazards and extend the filter life, reduces maintenance costs, and has fewer breakable and replaceable parts.

Another customer-focused feature of the PureFlo 3000 PAPR series is its miniaturized, fast-charging lithium-ion battery that offers four to five hours of run time in high-performance environments. Gentex's successful performance highlights its ability to leverage customer engagement to achieve greater penetration in industrial sectors. By having a finger on the pulse of customer needs, Gentex continually enhances its head top design, weight, quality, battery run time, and level of protection.

"Gentex has met the PAPR needs of a wide range of industries by uniquely offering integrated head, face, eye, and hearing protection solutions, along with respiratory protection in a single device," noted Rahul Arora."The company continues to set itself apart from the competition through an outstanding value proposition, wherein it leads with innovative products, is solution driven, and ensures the best customer experience."

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased return on investment (ROI) it gives customers, which, in turn, raises customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion.

Contact:

Claudia Toscano
P: 210.477.8417
E: claudia.toscano@frost.com

About Gentex Corporation (Gentex)

With a history of innovation that spans over 125 years, Gentex Corporation is a leading supplier of products that advance personal protection and situational awareness for global defense forces, emergency responders, and industrial personnel operating in high-performance environments. Our portfolio includes helmet system platforms, hearing protection and communications products, and capability upgrades for defense and security forces sold under the Gentex and Ops-Core brands, as well as PureFlo industrial respiratory protection systems. Privately held, Gentex is headquartered in Carbondale, Pennsylvania, and supports its global customers through a worldwide distributor network and six other facilities in the U.S., the U.K., and Australia. Learn more at www.gentexcorp.com.

Contact:

Nora Musgjerd
P: +1 570.282.8418
E: nmusgjerd@gentexcorp.com

© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.